Xeris Biopharma Holdings, Inc. (XERS) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | 9.87M | 20.04M | 18.43M | 182K | -10.03M | 1.98M | -8.3M | -10.35M | -20.3M | 6.29M | -14.61M | -13.74M |
| Operating CF Margin % | 11.87% | 23.36% | 24.78% | 0.25% | -16.69% | 3.29% | -15.3% | -21.53% | -49.96% | 14.16% | -30.24% | -36.16% |
| Operating CF Growth % | 198.4% | 914.84% | 321.94% | 101.76% | 50.59% | -68.58% | 43.16% | 24.71% | 22.33% | 139% | 17.71% | 33.31% |
| Net Income | 2.23M | 11.08M | 621K | -1.93M | -9.22M | -5.11M | -15.74M | -15.01M | -18.98M | -13.39M | -12.19M | -19.84M |
| Depreciation & Amortization | 3.05M | 3.05M | 3.05M | 3.16M | 3.14M | 3.13M | 2.68M | 3.15M | 3.21M | 3.26M | 3.36M | 3.36M |
| Stock-Based Compensation | 0 | 5.27M | 7.64M | 5.01M | 4.44M | 3.6M | 6.77M | 4.23M | 3.77M | 2.77M | 2.46M | 2.93M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | -3.32M | 749K | 307K | -1.25M | 2.84M | -416K |
| Other Non-Cash Items | 5.19M | 1.02M | 983K | 820K | 844K | 834K | -7.71M | -92K | -2.98M | -2.93M | -361K | -222K |
| Working Capital Changes | -603K | -373K | 6.14M | -6.88M | -9.24M | -474K | 9.02M | -3.39M | -5.63M | 17.83M | -10.71M | 445K |
| Change in Receivables | -5.25M | 2.7M | -703K | -6.72M | -5.92M | 723K | 1.3M | -5.03M | 1.78M | 6.77M | -15.74M | 635K |
| Change in Inventory | 851K | -4.01M | -4.08M | -7.57M | -3.62M | -3.14M | -1.05M | -2.27M | -2.33M | -1.4M | -2.15M | -7.43M |
| Change in Payables | 4.25M | -1.7M | 2M | -4.43M | 4.06M | -5.2M | 1.65M | -1.59M | -4.47M | -353K | 297K | 80K |
| Cash from Investing | -325K | -333K | -71K | -279K | -13K | 10.02M | 9.91M | 4.6M | -19.65M | 14.87M | 14.65M | 8.45M |
| Capital Expenditures | -325K | -333K | -363K | -279K | -13K | -220K | -87K | -397K | -164K | -132K | -345K | -1.55M |
| CapEx % of Revenue | 0.39% | 0.39% | 0.49% | 0.39% | 0.02% | 0.37% | 0.16% | 0.83% | 0.4% | 0.3% | 0.71% | 4.07% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 292K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10M |
| Cash from Financing | -8.84M | -266K | 13.85M | 942K | -3.14M | 398K | -83K | 659K | 35.19M | -49K | -72K | 556K |
| Debt Issued (Net) | 0 | 9.17M | 0 | 0 | 0 | 0 | 0 | 0 | 38.17M | 0 | 0 | 0 |
| Equity Issued (Net) | -8.84M | -9.43M | 13.85M | 942K | -8M | -166K | -83K | -51K | -3.43M | -49K | -72K | -25K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -17.02M | -1.54M | -478K | -860K | -8M | -166K | -83K | -51K | -3.43M | -49K | -72K | -25K |
| Other Financing | 0 | 0 | 0 | 0 | 4.86M | 564K | 0 | 710K | 459K | 0 | 0 | 581K |
| Net Change in Cash | 708K | 19.44M | 32.21M | 845K | -13.18M | 12.39M | 1.53M | -5.09M | -4.76M | 21.31M | -27K | -4.74M |
| Free Cash Flow | 9.54M | 19.71M | 18.07M | -97K | -10.04M | 1.75M | -8.39M | -10.74M | -20.47M | 6.15M | -14.96M | -15.29M |
| FCF Margin % | 11.48% | 22.97% | 24.29% | -0.14% | -16.71% | 2.92% | -15.46% | -22.36% | -50.36% | 13.86% | -30.95% | -40.23% |
| FCF Growth % | 195.03% | 1023.08% | 315.31% | 99.1% | 50.93% | -71.48% | 43.89% | 29.73% | 22.41% | 137.87% | 16.59% | 26.57% |
| FCF per Share | 0.05 | 0.11 | 0.10 | -0.00 | -0.07 | 0.01 | -0.06 | -0.07 | -0.15 | 0.04 | -0.11 | -0.11 |
| FCF Conversion (FCF/Net Income) | 4.42x | 1.81x | 29.68x | -0.09x | 1.09x | -0.39x | 0.53x | 0.69x | 1.07x | -0.47x | 1.20x | 0.69x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |